

This document is an unofficial translation of the corresponding Swedish document. In the event of any discrepancies between the text contained in this document and the Swedish document, the latter shall prevail.

Nomination Committee Proposal for Biotage AB's AGM 2011

Background

The Company's shareholders resolved at the Annual General Meeting held on 29 April 2010 that the Company forthwith shall have a Nomination Committee.

The Annual General Meeting 2010 resolved that the Chairman of the Board of Directors shall be elected member of the Nomination Committee, but not be acting as Chairman of the Nomination Committee. The Chairman was assigned to appoint, in consultation with the (by voting rights) major shareholders of the Company as per September 1, 2010, another three members. The names of such members should be published no later than six months before the Annual General Meeting 2011. The Nomination Committee shall appoint one of the members to be the Chairman of the Nomination Committee.

A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been formed for Biotage AB.

The members of the Nomination Committee are:

Staffan Josephson, Investor Growth Capital, Chairman of the Nomination Committee

Anders Walldov, Brohuvudet AB and private

Tommy Jacobsson, Varenne AB

Ove Mattsson, Chairman of the Board

The Nomination Committee shall, before the Annual General Meeting 2011, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, the determination of fees and matters pertaining thereto. The Nomination Committee has had continuous meetings and ongoing telephone contacts.

These meetings have primarily been devoted to an evaluation of the present board of directors, discussions about the number of board members, the need for recruitment of new board members, discussions concerning such potential new board members and board fees.

Statement by the Nomination Committee

Following interviews of board members the Nomination Committee has come to the conclusion that the number of board members is adequate for an efficient board. By reason thereof, the Nomination Committee will not propose any changes to the number of board members.

The Nomination Committee has discussed the composition of board members as well as the number of board members from a perspective of the company's present situation and future developments. These discussions have had the purpose to get a better

understanding of what requirements will put on the board going forward and have involved judgment of competencies and relevant experiences from the company's business environment. An overall guidance has been to have a composition of board members that has competencies and experiences necessary for Biotage. The Nomination Committee has taken into consideration the importance of striving for an equal number of men and women in the board.

The evaluation of the present board of directors has included a report from Ove Mattsson, Chairman of the Board, about the outcome from the board of directors' yearly evaluation of the work undertaken by the board during the year. The board meeting attendance has been high amongst the board members and it is the Nomination Committee's understanding that the work within the board is functioning well.

The board members that have been proposed for re-election have all declared that they are available. By reason of the above the Nomination Committee proposes re-election of the following board members: Ove Mattsson, Anders Walldov, Eva-Lotta Kraft, Thomas Eklund and Per-Olof Eriksson.

Staffan Lindstrand left his assignment on 27 October 2011 and is therefore not available for re-election as Board member. The Nomination Committee proposes the AGM to elect Dr. Nils Olof Björk as a new member of the Board. Dr. Björk has a long career with Alfa Laval where he during the years 1995-2002 was the Managing Director of Alfa Laval Japan, during the years 2002-2009 Dr. Björk was part of Alfa Laval's group management team and responsible for Mergers & Acquisitions and new technologies focused on energy, food, pharma and environment. Dr. Björk is since 2009 Senior Advisor and a Director of Tranter, Inc. chairman of Österlens Kraft AB and Österlens Kraft e.f., and since 2011 also president for Sällskapet Lundaakademiker.

Ove Mattsson is proposed as chairman of the board.

The Nomination Committee believes that the proposed constitution of the board is appropriate to meet the challenges of the company business, considering the art of the business, current business environment and other relevant conditions.

The Nomination Committee has concluded to propose that the board fee shall be increased with an aggregate amount of SEK 195,000 in relation to what was determined at the 2010 AGM.

All of the proposed board members are considered to be independent of the company and its executive management as well as being independent of the company's major shareholders, taking into consideration and in relation to the listing requirement of NASDAQ OMX Nordic Exchange Stockholm and the requirements of the Swedish Code of Corporate Governance for the board members independence. The proposal fulfills the requirements on independence as required by NASDAQ OMX Nordic Exchange Stockholm and the Swedish Code of Corporate Governance.

The Nomination Committee of Biotage will present the following proposals at the company's Annual General Meeting:

The Nomination Committee's proposal regarding chairman at the Annual General Meeting

The Nomination Committee proposes that Ove Mattsson shall chair the meeting.

The Nomination Committee's proposal regarding number of board members and deputy board members

The Nomination Committee proposes six board members and no deputy board members.

The Nomination Committee's proposal regarding fees to the board

The Nomination Committee proposes a fixed board fee in the aggregate amount of SEK 1,220,000 for the period up and until the end of the 2012 Annual General Meeting, to be distributed as follows, SEK 420,000 to the chairman and SEK 160,000 to the other board members.

In addition hereto the Nomination Committee proposes that the chairman of the audit committee shall receive SEK 50,000 and SEK 25,000 each to the other two members of the audit committee.

The Nomination Committee's proposal regarding fees to the auditor

The Nomination Committee proposes that fees payable to the auditors for the period up to and including the annual general meeting 2012 shall, as before, shall be paid against approved account.

The Nomination Committee's proposal regarding board members

The Nomination Committee proposes that Ove Mattsson, Thomas Eklund, Per-Olof Eriksson, Eva-Lotta Kraft and Anders Walldov, shall be re-elected as board members. The Nomination Committee proposes that Dr Nils Olof Björk shall be elected as new board member.

Information about each of the proposed board members is found below.

Ove Mattsson

Born: 1940.

Education: Ph.D., Docent Organic Chemistry.

Number of years as Biotage board member: 7 years, elected 2003, member of compensation and audit committee.

Other assignments: Chairman of the board in Aromatic AB. Board member in Arctic Island Ltd, Fabryo Corporation SRL and Tikkurila Oy. Member of Kungliga Ingenjörsvetenskapsakademien, IVA.

Shares in Biotage, own and related parties: 6,283,531 shares via endowment insurance.

Principal prior experiences: Former president of Nobel Industrier AB, COO for Akzo Nobel Coatings and member of Akzo Nobels executive management (Board of management).

Independence: Taking into consideration and in relation to the listing requirement of NASDAQ OMX Nordic Exchange Stockholm and the requirements of the Swedish Code of Corporate Governance for the board members independence it is the Nomination Committee's opinion that Ove Mattsson is independent in relation to the company, the executive management and major shareholders of the company.

Nils Olof Björk

Born: 1947.

Education: Ph. D. Inorganic Chemistry with focus on solution chemistry and thermodynamics. Studies in solid state chemistry and bio chemistry.

Other assignments: Advisor and a Director of Tranter, Inc. since 2009, chairman of Österlens Kraft AB and Österlens Kraft e.f., chairman of Taurus Energy AB (publ) and since 2011 also president for Sällskapet Lundaakademiker.

Shares in Biotage, own and related parties: Currently none.

Principal prior experiences: Dr. Björk has a long career with Alfa Laval where he during the years 1995-2002 was the Managing Director of Alfa Laval Japan, during the years 2002-2009 Dr. Björk was part of Alfa Laval's group management team and responsible for Mergers & Acquisitions and new technologies focused on energy, food, pharma and environment.

Independence: Taking into consideration and in relation to the listing requirement of NASDAQ OMX Nordic Exchange Stockholm and the requirements of the Swedish Code of Corporate Governance for the board members independence it is the Nomination Committee's opinion that Nils Olof Björk is independent in relation to the company, the executive management and major shareholders of the company.

Thomas Eklund

Born: 1967

Education: MBA Stockholm School of Economics

Number of years as Biotage board member: 4 years, elected 2006, member of the audit committee.

Other assignments: Board member of Vårdapotek Norden AB, Carmel Pharma AB, Neoventa Medical AB, Memira AB and CMA Microdialys AB.

Shares in Biotage, own and related parties: 22,000 shares.

Principal prior experiences: Managing Director, Investor Growth Capital.

Independence: Taking into consideration and in relation to the listing requirement of NASDAQ OMX Nordic Exchange Stockholm and the requirements of the Swedish Code of Corporate Governance for the board members independence it is the Nomination Committee's opinion that Thomas Eklund is independent in relation to the company, the executive management and major shareholders of the company.

Per-Olof Eriksson

Born: 1938.

Education: M.Sc. Royal Institute of Technology, Stockholm

Number of years as Biotage board member: 3 years, elected 2007.

Other assignments: Chairman of the board in Ferronordic Machine AB, CrossControl AB and Odlander, Fredriksson & Co AB. Board member of Investment AB Öresund, Kamstrup AB and Södersjukhuset AB. Member of Kungliga Ingenjörsvetenskapsakademien, IVA.

Shares in Biotage, own and related parties: 10,000 shares.

Principal prior experiences: CEO and President of Seco Tools AB and Sandvik AB.

Independence: Taking into consideration and in relation to the listing requirement of NASDAQ OMX Nordic Exchange Stockholm and the requirements of the Swedish Code of Corporate Governance for the board members independence it is the Nomination Committee's opinion that Per-Olof Eriksson is independent in relation to the company and the executive management and major shareholders of the company.

Eva-Lotta Kraft

Born: 1951.

Education: Masters of Science Chemical Engineering (Kungliga Tekniska Högskolan KTH), MBA in International Business Management (Uppsala Universitet).

Number of years as Biotage board member: 1 year, elected 2010.

Other assignments: Board member in ÅF AB, Nibe Industrier AB, Samhall AB, Boule Diagnostics AB and Siemens AB.

Shares in Biotage, own and related parties: 4,000 shares.

Principal prior experiences: Currently working with assignments as board member and other engagements. Previous experiences from working with leadership, development and marketing in international environments at FOI, Swedish Defence Research Agency, Siemens-Elema and Alfa Laval, amongst others.

Independence: Taking into consideration and in relation to the listing requirement of NASDAQ OMX Nordic Exchange Stockholm and the requirements of the Swedish Code of Corporate Governance for the board members independence it is the Nomination Committee's opinion that Eva-Lotta Kraft is independent in relation to the company, the executive management and major shareholders of the company.

Anders Walldov

Born: 1949.

Education: GBA Handelshögskolan i Lund, AMP Harvard Business School.

Number of years as Biotage board member: 1 year, elected 2010.

Other assignments: Board member in Brohuvudet AB, SevenDay Finans AB, Followit Holding AB (publ) and Wellnet AB.

Shares in Biotage, own and related parties: 7,000,000 shares.

Principal prior experiences: Private investor with more than 30 years experience from bank and finance, whereof approximately 20 years as CEO.

Independence: Taking into consideration and in relation to the listing requirement of NASDAQ OMX Nordic Exchange Stockholm and the requirements of the Swedish Code of Corporate Governance for the board members independence it is the Nomination Committee's opinion that Anders Walldov is independent in relation to the company, the executive management and major shareholders of the company.